(PRWEB) February 19, 2014
Transposagen Biopharmaceuticals Inc. announced today that it has partnered with the Medical College of Wisconsin (MCW) to provide its gene editing tools for MCW’s recent grant from the National Heart, Lung, and Blood Institute to create new genetically modified rat models for studying the genetics of human diseases.
Transposagen has extensive experience in the design and production of gene editing tools, including XTN™ TALENs for the production of genetically modified rats and other organisms. Through its premium gene editing tools programs, which include cell-based activity testing, Transposagen provides partners with a guarantee of successful gene modification projects. Recently, one of Transposagen’s pharmaceutical partners successfully genetically modified a target gene after 10 years of failed attempts using TALENs or Zinc Finger Nucleases (ZFNs) from other providers.
In addition to high efficiency gene editing nucleases, Transposagen holds exclusive licenses and patents to the piggyBac™ Gene Modification System, which can be used in combination with site-specific nucleases, such as XTN™ TALENs and CRISPRs for Footprint-Free™ Gene Editing in cells and animals. The Footprint-Free™ Gene Editing System is the world’s only source for clean editing down to a single base-pair with no unwanted mutations and the ability to select for rare events. Alternative engineering systems, such as CRE/lox and Flp/FRT, leave behind mutations in the genome that can result in gene silencing and toxicity.
Transposagen’s partnership with MCW is another example of the use of its industry-leading gene editing technology in academic labs around the world. Transposagen is actively seeking partnerships for gene editing projects and can help academic researchers receive grants, perform successful research and get published in top journals. Transposagen’s gene editing technology is also used by the majority of the top pharmaceutical companies for the creation of custom cell lines and animal models.